Login to Your Account



Mixed Jerini Phase III Data In HAE Perks Dyax Shares

By Randall Osborne


Monday, September 25, 2006
In the pull-ahead, fall-back race for a drug against hereditary angioedema (HAE), Dyax Corp. regained some lost ground with news that Icatibant - the synthetic peptidomimetic from would-be competitors Kos Pharmaceuticals Inc. and Jerini AG - missed its primary endpoints in one Phase III trial, but hit the primary endpoint in another. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription